# BridgeBio Oncology Therapeutics, Inc.: Form 8-K, filed Mar 26, 2026

- Company: [BridgeBio Oncology Therapeutics, Inc.](/companies/bbot.md) (CIK 1869105)
- Form: 8-K
- Filed: 2026-03-26
- Accepted by EDGAR: Mar 26, 2026, 16:52 ET
- Period: 2026-03-24
- Accession: 0001193125-26-126493
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1869105/000119312526126493/d126641d8k.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1869105/000119312526126493/

## Items reported

- Item 5.02: Departure or appointment of officers or directors

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1869105/000119312526126493/d126641d8k.htm

Filed Mar 26, 2026.
Source: SEC EDGAR, the filing index for accession 0001193125-26-126493. Last ingested by Listed: Nov 14, 2026, 20:40 ET. No prices; not investment advice.
